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ABsTRAcr A model for the action of vinblastine (VLB) on cells multiplying ex-
ponentially in vivo with a generation time, TG, has been derived. It is based on
the assumption that cells attempting to pass through mitosis in the presence of
VLB lose their proliferative capacity and that this lethal effect occurs only when
the cells are exposed to a concentration of VLB which is above a critical value,
Ck. The model leads to two predictions. First, that the percentage of cells surviving
at any time after exposure to a dose, D, of VLB is 100% if D < Dk and decreases
to 0% after a time, TG, following a dose D > Dk.2TG/T/2 , where Dk represents
the dose of VLB required to produce the concentration Ck, and T1/2 is the half-life
of the VLB in vivo. Second, that the time, TG, at which the percentage of cells
surviving an exposure to VLB, at doses greater than Dk*2U0/TIa, decreases to
zero should be equal to the generation time of the cells. Both of these predictions
were confirmed experimentally which indicates that the model adequately explains
the action of VLB in vivo.
INTRODUCTION
Although the leukopenic and tumorlytic activity of vinblastine (VLB) and the
general structure of this dimeric alkaloid have been known for some time (John-
son et al., 1963), there has been some uncertainty about the mechanism of action
of this drug. Recent experiments have shown that mouse L-cells exposed to VLB
in vitro accumulate in mitosis and concomitantly lose their proliferative capacity
(Bruchovsky et al., 1965). When such cells are exposed to VLB for one generation
time, most of the cells lose their ability to produce colonies. These experiments
have also indicated that VLB acts only upon cells entering into mitosis, causing
them to lose their proliferative capacity. Cells that have not entered this stage of
the cell cycle do not lose proliferative capacity although exposed to VLB.
It is reasonable to suppose that the action of VLB in vivo is similar to its action
in vitro. VLB is known to lead to the accumulation of mitotic figures in animals
injected with the drug (Cardinali et al., 1964) and the leukopenic and tumorlytic
actions of the drug may well be a result of the loss of proliferative capacity of divid-
ing marrow and tumor cells, respectively. An analysis of the action of VLB in vivo
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is hampered, however, by the limited accuracy of conventional assays for cell
viability in vivo and by the fact that the concentration of VLB cannot be as easily
controlled in vivo as it can in vitro. It is possible that proliferating cells may be
exposed to effective levels of VLB for only limited periods of time in vivo as a
consequence of the metabolism and excretion of the drug.
We have developed a sensitive quantitative transplantation procedure that may
be used to determine the fraction of transplanted tumor (lymphoma) cells that
have proliferative capacity (Bush and Bruce, 1964). We have also developed a
method to measure the growth-inhibiting activity in the serum of mice and have
used this method to measure the concentration of VLB activity in the serum of
mice injected intraperitoneally with VLB (Valeriote and Bruce, 1965). The
availability of these two assays together with the results of studies with VLB in
vitro has permitted us to develop and test a model for the action of VLB in vivo.
The model assumes that VLB in a concentration higher than a critical value leads to
the irreversible loss of proliferative capacity by those cells that pass into mitosis.
Experimentally, the data for survival of lymphoma cells following various doses of
VLB and various durations of exposure to VLB fit the model well. The data to be
presented thus support our assumptions that the action of VLB is similar in vitro
and in vivo. They suggest a simple method for measuring generation times of cells
in vivo and provide a rationale for the use of VLB in the treatment of rapidly
proliferating tumors.
MATERIALS AND METHODS
Mice. Five- to 6-week-old AKR/J mice were obtained from the Jackson Me-
morial Institute, Bar Harbor, Maine. In the experimental groups 5-week-old females
weighing between 21 and 24 g were used. They were injected via the tail vein with 100
lymphoma cells and 96 hr later were injected intraperitoneally with VLB. For assay of
cell suspensions mice of either sex were used. All mice were kept 5 to a cage.
Transplanted Cell Lines. The transplanted cell line used in these experiments
arose from a spontaneous lymphoma in an 8-month-old female AKR/J mouse. The
properties of the line have been described previously (Bruce and Meeker, 1964). The
line has been retransplanted into new AKR hosts weekly. Cells from transplantations
114 to 130 were used as the source of lymphoma cells in the experiments reported here.
Growth of the cells through this period was similar to that described previously.
Preparation of Cell Suspensions. Cell suspensions were prepared from 10
femoral marrows of lymphomatous mice by a method previously described (Bruce and
Meeker, 1964). A fraction of the suspension was diluted, and 500 to 1000 cells were
counted in a hemocytometer. The initial suspension was then diluted to achieve the
concentrations required for the subsequent injections. All suspensions were kept in
icewater prior to use and were injected within a period of 2 hr following this preparation.
Assay for Lymphoma Colony-Forming Cells. Cell suspensions from animals
bearing lymphoma cells were assayed for the number of cells which were capable of
producting colonies in the spleens of mice by a method described in detail previously
(Bush and Bruce, 1964). A measured fraction of the suspension was injected intra-
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venously into a group of 20 mice. The mice were killed 8 days later and the spleens
were examined for macroscopic colonies. The mean number of colonies per spleen was
determined and the number of lymphoma colony-forming units (CFU) in the initial
suspension was calculated.
Vinblastine (VLB). The vinblastine sulfate (E. Lilly and Co., Toronto,
Ontario) was obtained as a lyophilized powder and was dissolved in distilled water. All
solutions were injected as a single injection intraperitoneally in a volume of 1.0 ml.
MODEL FOR THE ACTION OF VLB
The model for the action of VLB on proliferating cells in vivo rests upon the fol-
lowing 6 assumptions:
(a) The number of proliferating cells increases exponentially with time. The
assumption is valid in the case of the colony-forming lymphoma cells used in this
investigation since these cells have been shown to increase exponentially in number.
Following the transplantation of 106 cells into AKR hosts the number of colony-
forming units increases from about 5 to 105 per femur in a period of 7 days
(Bruce and Meeker, 1964).
(b) All cells are in cell cycle with the same generation time, TG. Data obtained in
studies of generation times of mammalian cells in vitro show that some cells in a
population may have generation times shorter or longer than the mean generation
time (Hsu, 1960). Since the fraction of such cells is presumably quite small and
since the cell line used in these studies has grown in exponential phase with a
doubling time, TD, of 11 hr for many generations, we have chosen to assume that
all cells have the same generation time in order to simplify the mathematical treat-
ment. The effect of a distribution of generation times on the model is discussed
below. It may be noted that we distinguish between the generation time, TG, and
doubling time, TD, of cells since death and loss of cells in cycle may lead to a situa-
tion where TD is greater than TG.
(c) There is no important net migration of proliferating cells in vivo after treat-
ment with VLB. While some migration of cells may certainly occur, this assump-
tion is reasonable since the cells to be studied form colonies in vivo and thus
demonstrate a propensity to remain localized.
(d) The activity of VLB in the fluid surrounding cells in vivo decreases ex-
ponentially with time and, at any time, depends directly upon the injected dose.
This assumption is based on data for VLB activity in the serum of mice from 1 to
10 hr following the intraperitoneal injection of from 0.2 to 2.0 mg VLB per mouse
(Valeriote and Bruce, 1965). We are therefore assuming that the concentration
surrounding the cells is directly proportional to that in the serum.
(e) Only cells passing through mitosis are killed by exposure to VLB. We here
assume that the action of VLB in vivo is similar to its action on mammalian cells
in vitro (Bruchovsky et al., 1965).
(f) The dose-response curve for proliferating cells exposed to VLB is discon-
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tinuous. Below a critical concentration of VLB, Ck, there is 100% survival of cells
while above this concentration there is 0% survival. This assumption is also based
on observations made with cells growing in vitro. It has been found that such cells
lose proliferative capacity over a relatively short range of concentrations of VLB
near 3 x 10-9 g per ml (Valeriote and Bruce, 1965).
In brief, we are assuming that the growth of cells in vivo is uniform, that the cells
in the animal are exposed to the levels of growth-inhibiting activity of VLB that
are measured in the serum, and that the action of VLB is the same in vivo and in
vitro.
When cells are growing exponentially, are in uniform cycle, and are not migrat-
ing (assumptions a, b, and c) the number of viable cells passing through mitosis (or
any other point in the cell cycle) in a time, dt, at time t, is
dN = A 2 /TD dt (1)
where A is a constant corresponding to the rate of appearance of new cells due to
division at time t = 0 and TD is the doubling time for the cells. If cells lose their
proliferative capacity only when exposed to VLB during mitosis (assumption e)
and if the cells are so exposed for a length of time equal to or greater than the gen-
eration time, TG, of the cells, then all proliferating cells will be inactivated. If,
however, they are in contact with the drug for a period, T, less than TG then a fraction
of the cells will survive. The fraction, F(T), which survives when cells are in contact
with the drug for the period T is
To ~ ~ fpTora
TD IIT TGTTaT) GTF(T) = J A .2 dt/J| A .2 TD dt = (2" /TD - 2" TD)/(2TG/TD - 1) (2)
In the situation in which there is no death of cells occurring so that TG = TD, this
equation reduces to:
F(r) = 2 - 2 (3)
Both equations (2) and (3) have a value F = 1 when T = 0 and decrease to
F = 0 whenT = TGa
We have assumed (assumption d) that the concentration of growth-inhibiting
activity in the serum, C, at a time, t, following a single, intraperitoneal injection of
VLB of dose, D mg, is given by:
C(t) = B. D.2- I/Tz /s
where B is a constant relating growth-inhibiting activity and injected dose and T1/2
represents the half-life of the growth-inhibiting activity of VLB in the serum. If
VLB kills cells passing through mitosis only when the concentration, C, is greater
than Ck (assumption f), the duration of this inhibition, that is the time, tk, required
for the VLB concentration to reach Ck, will depend on the dose of VLB injected
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and will be given by:
tk = 0 for D < Dk =Ck/B
and
tk = T1/2 log2 (D/Dk) for D > Dk (4)
Equations (3) and (4) may be combined by substituting tk forT. to give the fraction
of cells, G(D), which survive a dose, D, after exposure to VLB for a time TG:
G(D) = l for D < Dk
G(D) = 2 - 2(TI2,/TG)(109g. D/Dl) for Dk < D < Dk 2TG/7/2 (5)
G(D) = 0 for D > Dk.2T0/T1/2
The model thus predicts the extent of survival of cells exposed to VLB in vivo
both for various doses of VLB, when the cell survival is assayed at time TG [equa-
tions (5)] and for various durations of exposure to VLB, when the concentration
is above Ck [equation (3)]. If, in the former case, the fraction surviving is assayed
at a time greater than TG, the survival curve will have the same form and the same
end-points as equations (5) although the dose-response curve will have a slightly
different shape since some surviving cells may pass through mitosis more than once
in this case. In our studies we chose to examine survival to the various doses of
VLB after a 24 hr exposure since we had no prior knowledge of the value of TG.
We have also chosen to assume that the generation time and doubling time were
equal in our fit of the experimental data. Our results suggests that they are, indeed,
nearly equal.
EXPERIMENTAL RESULTS
Effect of Dose of VLB upon Survival of Colony-Forming Ability. The model
which we have developed for the action of VLB in vivo predicts 100%S survival of
cells when the animals are injected with doses less than or equal to the dose Dk,
which gives the critical concentration, C*. Above this dose, it predicts that survival
will decrease to zero after a time Ta when the cells are exposed to a dose 2TG/r1/.
times the critical dose. The data of previous studies permit us to estimate these
parameters and thus the shape of the dose-response curve. Mouse L-cells grown
in tissue culture and exposed to concentrations of greater than 3 X 10-9 mg VLB
per ml die in mitosis; this concentration is reached in the serum of mice injected
with 1.0 X 10' mg VLB (Valeriote and Bruce, 1965). The doubling time of the
cells which we are studying is 11.2 hr; the half-life of VLB is 3.5 hr. The ratio TG/T112
is thus expected to be approximately 3.1. We would therefore expect that mice ex-
posed to doses of less than 1.0 X 10-' mg VLB would contain the same number of
proliferating cells as the controls while animals receiving 23.1 or approximately
8 times this dose would contain no proliferating cells.
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To test these predictions, groups of 5 mice each were injected with 106 lymphoma
cells. Ninety-six hours later the groups were given single, intraperitoneal injections
of VLB of from 10-' to 1 mg/mouse. Twenty-four hours following the injection they
were killed and pooled cell suspensions from femoral marrow were assayed for
their content of colony-forming cells. Five separate experiments were carried out,
the results of which appear in Fig. 1. The data are well fitted by equations (5) where
Dk = 5.5 X 0-3 mg/mouse and TI/TI,2 = 3.0, with TD = T,G A single experiment
in which the dose-response curve for lymphoma cells in the spleen was measured
yielded the same results. The range of doses over which the survival of lymphoma
cells decreases from the control value to zero is in excellent agreement with that
predicted. However, the Dk for these cells was found to be 5.5 times greater than
that expected from the in vitro data with mouse L-cells. This difference will be con-
sidered in the Discussion section.
Effect of Duration of Exposure to VLB upon Survival of Colony-Forming
Ability. The model proposed for the action of VLB in vivo also predicts that the
survival of cells following an exposure to VLB should be independent of dose for
doses greater than D,-2Ta/T"/; and that when the injected dose is larger than this
dose, the surviving fraction reaches zero when the duration of exposure to VLB is
equal to or greater than the generation time. Data from the previous section would
therefore predict that the survival will decrease to zero at 11 hr when more than 5 X
102 mg VLB is injected, and that the shape of the disappearance curve would be
independent of dose.
To test these predictions, groups of 5 mice each were injected with 108 lymphoma
1.4
1- 1.2 {
THEORETICAL CURVE FOR
x1.0 _is_ _
-
< . \ | ~~~~~~~~~~~~~~DK=5.5 X 1O3mg
0.8 TG/ Ti/2 = 3.0
TD =TG
L0.6-
0.4 -
J 0.2
0 10 1021
DOSE VLB (mg/mouse)
FIGURE 1 Effect of dose of VLB upon survival of lymphoma colony-forming units
(CFU) measured 24 hr following administration of VLB. The results shown are
from 5 separate experiments. Confidence intervals represent one standard error of
the mean.
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cells and 96 hr later were injected with either 0.1 or 0.5 mg VLB. The mice were
killed from 0 to 10 hr later and pooled femoral marrow suspensions were assayed
for their content of colony-forming cells. The results of three experiments are given
in Fig. 2. No difference in survival was found between the two doses used, both
curves approaching zero survival at 10 hr. The data are well fitted by equation (3)
where TG = 10 hr and TD = TG. The generation time of the lymphoma cells in vivo
thus appears to be 10 hr, in close agreement with the doubling time.
DISCUSSION
We have proposed a model for the action of VLB in vivo based primarily on
previous data obtained in vitro (Bruchovsky et al., 1965, and Valeriote and Bruce,
1965). This model predicts the dependence of survival of colony-forming lymphoma
cells as a function of both the dose of VLB, and the duration of exposure of these
cells to VLB. Our results are in excellent agreement with the model, thus support-
ing the assumption that the action of VLB in vivo is the same as its action in vitro.
Two slight discrepancies between the predictions of the model and the experi-
mental results deserve attention. First, it can be seen from Fig. 2 that the survival
of lymphoma colony-forming cells does not decrease to zero at the time TG is
predicted by equator (3) but that 5% of the cells still retain proliferative capacity
after this duration of exposure. The difference may be understood most readily as
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FIGURE 2 Effect of duration of exposure of VLB upon survival of lymphoma colony-
forming units (CFU). Solid and open symbols represent an administered dose of 0.5
mg/mouse for the former and 0.1 mg/mouse for the latter. Confidence intervals
represent one standard error of the mean.
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an inadequacy in assumption b, that all cells have the same generation time, Ta.
Since some cells have generation times longer than TG, a fraction of these, when
exposed to VLB for a time TG, will not have passed through mitosis. These cells
would presumably survive. Second, lymphoma cells in vivo appear to be somewhat
less sensitive to the action of VLB than does a line of mouse L-cells in culture. There
was found to be a 5.5-fold difference in sensitivity which may be a consequence of
a difference between the intercellular and serum concentrations of VLB (an in-
adequacy in assumption d) or may represent a real but small difference in the
sensitivity of the two cell lines studied.
The results of these investigations are of practical interest in two respects.
Firstly, the methods used have provided a technique for determining the generation
time of lymphoma cells growing in vivo. The survival of these cells is simply de-
termined at intervals for a period of time following the injection of a large dose
of VLB and the time at which the survival approaches zero corresponds to the
generation time. The method thus provides a means for determining the generation
time of cells growing in vivo where conventional autoradiographic techniques can-
not be used, but where quantitative assays for cell viability are available. Secondly,
the model suggests a rationale for the chemotherapy of rapidly proliferating tumors
with agents similar to VLB. It would indicate that the maximum inactivation of
the cells of such tumors can be accomplished only when the concentration of the
drug exceeds the critical value for the tumor cells for a period of time in excess of
the generation time of the cells. To achieve these conditions, estimates of Dk, T1/2,
and TG are necessary.
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